Announcement • Jun 03
X Bioscience Public Company Limited Announces Appointment of Ramjai Sriporamin to Chief Financial Officer, Effective June 1, 2026 X Bioscience Public Company Limited had resolved to approve the appointment of Ms. Ramjai Sriporamin as Chief Financial Officer, effective from June 1, 2026 onwards. Announcement • Jun 02
X Bioscience Public Company Limited Announces Board Changes X Bioscience Public Company Limited had acknowledged the resignation of Ms. Naphat Tavisaengsiri from her position as Director, effective May 28, 2026. The company had acknowledged the resignation of Mr. Yuthaveera Achawangkul from his positions as Independent Director and Member of the Nomination and Remuneration Committee of the Company, effective May 30, 2026. The Board of Directors’ Meeting resolved to approve the appointment of Dr. Poramin Nillaphan as Independent Director, Audit Committee Member, and Nomination and Remuneration Committee Member of the Company in replacement of Ms. Naphat Tavisaengsiri. The term of office shall be equal to the remaining term of the resigned director (expiring at the Annual General Meeting of Shareholders for the year 2027). Such appointment shall be effective from May 29, 2026 onwards. The Board of Directors’ Meeting resolved to approve the appointment of Asst. Prof. Dr. Radchada Lurang as Independent Director, Audit Committee Member, and Nomination and Remuneration Committee Member of the Company in replacement of Mr. Yuthaveera Achawangkul. The term of office shall be equal to the remaining term of the resigned director (expiring at the Annual General Meeting of Shareholders for the year 2028). Such appointment shall be effective from June 1, 2026 onwards. Following the appointment of the above directors, the structure of the Company’s Board of Directors comprised the following persons as Directors and/or Independent Directors of the Company: Mr. Supoj Pannoi, Chairman of the Board of Directors /Independent Director /Audit Committee; Miss Saowanee Khaoubol, Vice Chairman of the Board of Director /Director /Acting Chief Executive Officer; Mr. Amnart Lertpresertwong, Director; Miss Thansuda Rungruang, Director; Mr. Phurit Wongkham, Director; Mr. Sarayut Rueangsuwan, Independent Director /Chairman of the Audit Committee /Chairman of the Nomination and Remuneration Committee; Dr. Poramin Nillaphan, Independent Director /Audit Committee /Nomination and Remuneration Committee; Asst. Prof. Dr. Radchada Lurang, Independent Director /Audit Committee /Nomination and Remuneration Committee. New Risk • May 23
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -฿116m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-฿116m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 39x increase in shares outstanding). Minor Risks Revenue is less than US$5m (฿159m revenue, or US$4.9m). Market cap is less than US$100m (฿1.09b market cap, or US$33.5m). 
